Clinical Trials Using Anti-HER3 Antibody-drug Conjugate U3 1402

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-HER3 Antibody-drug Conjugate U3 1402. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

    This study has two parts: dose escalation and dose expansion. The primary objectives are: - For Dose Escalation, to assess the safety and tolerability of U3-1402 in the study population and to determine the recommended dose for expansion of U3-1402 in the study population - For Dose Expansion, to investigate the antitumor activity of U3-1402 The number of treatment cycles is not fixed in this study. Participants will continue study treatment (for approximately 36 months) until they decide not to (withdraw consent), their disease gets worse [progressive disease (PD)], or side effects become unacceptable (unacceptable toxicity) or other stopping reasons have been met.
    Location: 7 locations

  • A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

    This study is designed to primarily evaluate the safety and efficacy of U3-1402 in participants with advanced or metastatic colorectal cancer (CRC) who have received at least 2 prior lines of therapy and will explore clinical benefit according to human epidermal growth factor receptor 3 (HER3) tumor expression level in otherwise refractory tumors.
    Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey